Acrivastine + Pseudoephedrine

Acrivastine + Pseudoephedrine is used for: Seasonal Allergic Rhinitis, Nasal Congestion

Seasonal Allergic Rhinitis or Nasal Congestion 8 mg/60 mg (1 capsule) PO q4-6h >14 days continuous treatment efficacy not adequately investigated

Seasonal Allergic Rhinitis or Nasal Congestion <12 years: Safety and efficacy not established >12 years: 8 mg/60 mg (1 capsule) PO q4-6h >14 days continuous treatment efficacy not adequately investigated

Renal Impairment CrCl>48mL/min: Dose adjustment not necessary CrCl <48mL/min: Not recommended

Hypersensitivity to acrivastine or other alkylamine antihistamines Hypersensitivity to pseudoephedrine or other sympathomimetic amines Severe hypertension Severe coronary artery disease Patients taking monoamine oxidase (MAO) inhibitors and for 14 days after stopping use of an MAO inhibitor

Due to potential for sedation, assess individual responses before engaging in any activity requiring mental alertness, such as driving a motor vehicle or operating machinery Concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of CNS performance and should be avoided Not adequately studied for relieving common cold symptoms

Pregnancy Category: B Lactation: Unknown whether acrivastine is distributed in breast milk, caution advised ; pseudoephedrine is excreted in human milk, caution advised

MAO inhibitors and beta-adrenergic agonists increase the effects of sympathomimetic amines. Concomitant use of sympathomimetic amines with MAO inhibitors can result in a hypertensive crisis. Because MAO inhibitors are long-acting, Acrivastine + Pseudoephedrine Capsules should not be taken with an MAO inhibitor or for 14 days after stopping the use of an MAO inhibitor. Because of their pseudoephedrine content, Acrivastine + Pseudoephedrine Capsules may reduce the antihypertensive effects of drugs that interfere with sympathetic activity. Care should be taken in the administration of Acrivastine + Pseudoephedrine Capsules concomitantly with other sympathomimetic amines because the combined effects on the cardiovascular system may be harmful to the patient. Concomitant administration of Acrivastine + Pseudoephedrine Capsules with alcohol and other CNS depressants may result in additional reductions in alertness and impairment of CNS performance and should be avoided. Contraindicated (16) dihydroergotamine dihydroergotamine inhaled dihydroergotamine intranasal ergoloid mesylates ergonovine ergotamine isocarboxazid linezolid methylergonovine phenelzine procarbazine rasagiline selegiline selegiline transdermal thalidomide tranylcypromine Serious - Use Alternative (51) alfentanil amisulpride amitriptyline amoxapine benzhydrocodone/acetaminophen buprenorphine buprenorphine buccal buprenorphine subdermal implant buprenorphine transdermal buprenorphine, long-acting injection cabergoline clomipramine cocaine topical codeine desipramine desvenlafaxine deutetrabenazine doxapram doxepin duloxetine fentanyl fentanyl intranasal fentanyl iontophoretic transdermal system fentanyl transdermal fentanyl transmucosal hydrocodone hydromorphone imipramine iobenguane I 123 iobenguane I 131 isoflurane levomilnacipran lofepramine maprotiline methadone methocarbamol methoxyflurane metoclopramide intranasal milnacipran morphine nortriptyline oxycodone oxymorphone ozanimod protriptyline selinexor sevoflurane tramadol trazodone triazolam trimipramine

Side effects of Acrivastine + Pseudoephedrine : 1-10% Somnolence Nervousness Insomnia Dry mouth <1% Headache Dizziness Asthenia Nausea Dyspepsia Pharyngitis Cough increase Dysmenorrhea

Acrivastine exhibits H1-antihistaminic receptor activity, which prevents histamine from binding to its receptor in target cells Pseudoephedrine: Indirect sympathomimetic agent, releases norepinephrine from adrenergic nerves